The list of winners for the 2025 Crystal Ball Awards for Listed Companies organized by Weekly on Stocks was recently unveiled. China Medical System Holdings Limited (the “Group” or “CMS”) has been honored with two prestigious awards — the 2025 “Shareholder Return Crystal Ball Award“ and the “ESG Crystal Ball Award“ for Listed Companies — in recognition of its outstanding capital market performance and leading ESG practices. Launched in 2007 by Weekly on Stocks, the “Crystal Ball Awards” have become one of the three most influential annual award programs in China’s capital market, renowned for its professionalism, authority, and impartiality. The awards enjoy broad recognition among regulators, listed companies, and institutional investors. CMS has entered a new stage as “an innovation-driven, multinational pharmaceutical company with a fully integrated R&D, manufacturing, and commercialization value chain“. Currently, the Group’s innovation pipeline has expanded to approximately 40 products, among which 5 innovative drugs have been approved for marketing, and another 5 products are under review for marketing […]
Learn More
China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”), for which the Group holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights, has obtained the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 29 September 2025. The NMPA has agreed to conduct the clinical trial of MG-K10 for the treatment of Chronic Obstructive Pulmonary Disease (COPD). About MG-K10 MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13, for the treatment of type 2 inflammatory diseases. Currently marketed anti-IL-4Rα drugs require biweekly dosing, while MG-K10 has a longer half-life, enabling a four-week dosing frequency. It is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be […]
Learn MoreChina Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Group on 22 April 2025 for details) together with its subsidiaries holding the co-development rights (except for atopic dermatitis (AD)) and the exclusive commercialization rights of Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”) received the drug clinical trial approval notice issued by National Medical Products Administration (“NMPA”) on 28 September 2025. The NMPA has agreed to conduct a Phase III clinical trial of MG-K10 for chronic spontaneous urticaria (CSU). About MG-K10 MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13, for the treatment of type 2 inflammatory […]
Learn MoreThe news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.
